Beam Posts Positive Data on Base Editing Treatment for AATD

Beam posts positive data on base editing treatment for AATD

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins in a small study.

Beam sets hopes on accelerated approval of AATD gene therapy

Beam presented data from the Phase I/II trial of BEAM-302 where it showed disease-modifying qualities.The post Beam sets hopes on accelerated approval of AATD gene therapy appeared first on Clinical Trials Arena.

Beam Therapeutics Announces Update on BEAM-302

Open the article to view the coverage from Alpha-1 Foundation

Beam looks to accelerated approval for AATD base editing after promising update

Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo responsible for a rare genetic disease. On Wednesday,